Sichuan Kelun-Biotech Biopharmaceutical revenue and financials
$478.00Change from previous close: +1.75%Absolute change: +$8.20
In the fiscal year ended December 2025, Sichuan Kelun-Biotech Biopharmaceutical reported revenue of ¥2.06B (+6.46% year over year). The net loss was ¥381.97M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +6.46%
- 2025 vs 2024
- Net margin
- -18.6%
- 2024: -13.8%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 2,058 | 1,933 | 1,540 | 804 | — |
| Cost of revenue | 579 | 659 | 781 | 277 | — |
| Gross profit | 1,479 | 1,274 | 759 | 527 | — |
| Selling, general and administrative | 285 | 129 | 66.2 | 22.9 | — |
| Research and development | 1,320 | 1,206 | 1,031 | 846 | — |
| Operating income | -466 | -211 | -453 | -394 | — |
| EBIT | -350 | -139 | -383 | -419 | — |
| EBITDA | -249 | -47.4 | -308 | -351 | — |
| Interest expense | 6.2 | 3.8 | 84.3 | 149 | — |
| Pre-tax income | -356 | -143 | -468 | -567 | — |
| Income tax | 26.2 | 124 | 106 | 48.7 | — |
| Net income | -382 | -267 | -574 | -616 | — |
| Net income to common shareholders | -382 | -267 | -522 | -548 | — |
| Basic EPS | -1.66 | -1.20 | -2.84 | -2.54 | — |
| Diluted EPS | -1.66 | -1.20 | -2.84 | -2.54 | — |
| Average shares (basic) | 231 | 222 | 184 | 216 | — |
| Average shares (diluted) | 231 | 222 | 184 | 216 | — |